Sublingual Misoprostol in Reduction of Caesarean Blood Loss

• Status: Not yet recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

Caesarean delivery is inevitably associated with a higher amount of blood loss vis-à-vis primary postpartum haemorrhage, when compared to vaginal delivery. Oxytocin use in tropical developing countries for the reduction blood loss at caesarean section have been met with challenges of ineffectiveness due to poor transportation, inadequate storage and drug adulteration. Therefore, there is a need for an effective, temperature stable uterotonic with a lesser risk of adulteration. The study is aimed at evaluating the effectiveness and safety of adjunctive sublingual misoprostol in reducing intraoperative blood loss at caesarean section.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OZORI EBIOGBO STANLEY
• Treatments: Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• Pregnant women at term (37+0 weeks to 41+6 weeks gestational age) for elective or non-elective caesarean sections

• Pregnant women who have risk factor for primary postpartum haemorrhage

• Pregnant women who consent to participate in the study

Exclusion Criteria:

• Pregnant women who withhold consent to participate in the study

• Caesarean sections for dire emergencies (umbilical cord prolapse, suspected fetal distress and active antepartum haemorrhage)

• Previous caesarean sections or other uterine surgeries

• Pregnant women with no risk factor for primary postpartum haemorrhage

• Allergy to misoprostol use

• Known history of hepatic, renal and haematological disorders

• Caesarean section to be done under general anaesthesia

• Fever (temperature ≥ 37.5 degrees centigrade)

• Pre-operative anaemia (pre-operative haematocrit level < 30 %)

• Pregnant women who are unconscious or have eclampsia